Folotyn

Active Ingredient(s): Pralatrexate
FDA Approved: * September 24, 2009
Pharm Company: * ALLOS THERAPEUTICS, INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Folotyn Overview

Pralatrexate, sold under the brand name Folotyn, is a medication used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).[1][2] Pralatrexate was approved for medical use in the United States in September 2009, as the first treatment for Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.[2][3] Contents 1 Medical uses 2 Mechanism 3 Discovery 4 Society and culture 4.1...

Read more Folotyn Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pralatrexate

Recent Folotyn Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Folotyn: (3 results)

Sorted by National Drug Code

• 48818-001 Folotyn 20 mg/ml Intravenous Injection by Allos Therapeutics
• 72893-003 Folotyn 20 mg/ml Intravenous Injection by Acrotech Biopharma LLC
• 72893-005 Folotyn 40 mg/2ml Intravenous Injection by Acrotech Biopharma LLC

Other drugs which contain Pralatrexate or a similar ingredient: (1 result)

• PRALATREXATE

Related Folotyn Topics: